Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ: BMRN )

62.59 +0.65 (+1.05%)
Streaming Delayed Price Updated: 12:48 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Is BioMarin Ready To Rebound After FDA Approval Of Roctavian?
BioMarin gets FDA approval for Roctavian and earned an upgrade because of it; shares may be ready to rebound but there are still hurdles. 
Via MarketBeat
Exposures Product Safety
BioMarin Presents ~20% Upside Amid Voxzogo's Success and Slow Roctavian Uptake, Analyst Says
BMO Capital Markets has upgraded BioMarin Pharmaceutical Inc (NASDAQ: BMRN) to Outperform from Market Perform, and the price target remains at $102,  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 5, 2023
Via Benzinga
What 13 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Via Benzinga
What 9 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Via Benzinga
Death Cross Looms Over Biomarin Pharmaceutical Investors
Via Benzinga
What 17 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Via Benzinga
BioMarin's Roctavian US Launch: Focus on Commercial Strategy Amid EU Failures, Analyst Points Out
On Thursday, The FDA approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Roctavian (valoctocogene roxaparvovec-rvox) gene therapy for adults  
Via Benzinga
Amazon Hires Dozens of Former FTC Officials, Volkswagen Discusses With Tesla to Adopt North American Charging Standard, FDA Approves First Hemophilia A BioMarin Gene Therapy: Today's Top Stories
New York Post 
Via Benzinga
BioMarin's Delayed Roctavian Scores FDA Nod As First Hemophilia A Gene Therapy In US
The FDA approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Roctavian (valoctocogene roxaparvovec-rvox) gene therapy for adults with severe hemophilia A (congenital factor VIII (FVIII) deficiency... 
Via Benzinga
NVIDIA To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Friday
Truist Securities boosted the price target for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from $125 to $140. Truist Securities analyst Robyn Karnauskas maintained a Buy rating. BioMarin Pharmaceutical... 
Via Benzinga
A Preview Of Biomarin Pharmaceutical's Earnings
Via Benzinga
Where Biomarin Pharmaceutical Stands With Analysts
Via Benzinga
3 Biotech Stocks to Buy With Explosive Upside Potential
These three biotech stocks with high upside potential also display some significant risk, but less so than many of their small-cap peers. 
Via InvestorPlace
NASDAQ: BMRN Long Term Investor Notice: Lawsuit Against Directors at BioMarin Pharmaceutical Inc. Filed
San Diego, CA -- (SBWIRE) -- 06/20/2023 -- The Shareholders Foundation announced that an investor in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) filed a lawsuit against certain directors of... 
Via SBWire
3 Biotech Stocks That Could Skyrocket in the Next 12 Months
These promising biotech stocks are risky but offer tremendous upside generating stellar long-term returns in the upcoming 12 months. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Biotech Stocks With Blockbuster Potential
Although risky, these biotech stocks with blockbuster potential may skyrocket should regulatory winds favor their therapeutics. 
Via InvestorPlace
Why PTC Therapeutics Could Be Victorious In Its Rare-Disease Battle Against BioMarin Pharmaceuticals
The company is working on a treatment for PKU, a disorder that can lead to intellectual disabilities. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
7 Biotech Stocks That Could Cure Your Portfolio Woes
If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill. 
Via InvestorPlace
BioMarin Pharmaceutical Stock Shows Rising Relative Strength
BioMarin Pharmaceutical stock had its Relative Strength Rating upgraded to 77 on Thursday, up from 70 a day earlier. 
Via Investor's Business Daily
3 "Expensive" Growth Stocks That Are a Lot Cheaper Than You Realize
The nosebleed trailing-12-month price-to-earnings ratios for these supercharged growth stocks fails to tell the full story. 
Via The Motley Fool
BioMarin Pharmaceutical Stock Sees IBD RS Rating Improve To 74
A Relative Strength Rating upgrade for BioMarin Pharmaceutical shows improving technical performance. Will it continue? 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
Via Benzinga
Why did Sarepta Therapeutics Stock Plummet?
SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating. 
Via MarketBeat
Exposures Product Safety
After FDA Delays Hemophilia Gene Therapy, BioMarin's Dwarfism Drug Under FDA Review For Expanded Use
Via Benzinga
Why BioMarin Shares Are Plunging Today?
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares are falling in reaction to positive data from BridgeBio Pharma Inc's (NASDAQ: BBIO) dwarfism drug, heating the competition. 
Via Benzinga
BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study
The company is testing a drug for children with achondroplasia, a cause of dwarfism. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.